These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 14668942)

  • 21. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical remission as measured by a decrease in intact parathyroid hormone levels after administration of cinacalcet in patients with severe hyperparathyroidism.
    Battistella M; Hamandi B; Pui C; Oreopoulos D; Richardson R; Jassal SV
    Nephrol Dial Transplant; 2008 Feb; 23(2):773-4. PubMed ID: 17977873
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical issues regarding cinacalcet hydrochloride in Japan.
    Yokoyama K
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S12-4. PubMed ID: 19765252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cinacalcet ameliorates cardiac fibrosis in uremic hearts through suppression of endothelial-to-mesenchymal transition.
    Wu M; Tang RN; Liu H; Pan MM; Lv LL; Zhang JD; Crowley SD; Liu BC
    Int J Cardiol; 2014 Feb; 171(3):e65-9. PubMed ID: 24382406
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
    Serra AL; Schwarz AA; Wick FH; Marti HP; Wüthrich RP
    Nephrol Dial Transplant; 2005 Jul; 20(7):1315-9. PubMed ID: 15941845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cinacalcet: Amg 073, calcimimetics--Amgen/NPS Pharmaceuticals.
    Drugs R D; 2003; 4(1):39-41. PubMed ID: 12568635
    [No Abstract]   [Full Text] [Related]  

  • 28. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation.
    Borchhardt KA; Diarra D; Sulzbacher I; Benesch T; Haas M; Sunder-Plassmann G
    Am J Nephrol; 2010; 31(6):482-9. PubMed ID: 20431285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating hyperparathyroidism with cinacalcet HCl (Sensipar).
    Sloand JA
    Nephrol Nurs J; 2007; 34(3):341-2. PubMed ID: 17644877
    [No Abstract]   [Full Text] [Related]  

  • 30. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
    Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
    J Clin Pathol; 2011 Sep; 64(9):756-60. PubMed ID: 21565858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.
    Fukagawa M; Yumita S; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S;
    Nephrol Dial Transplant; 2008 Jan; 23(1):328-35. PubMed ID: 17717030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging roles of cinacalcet hydrochloride in the management of CKD-MBD.
    Fukagawa M; Suzuki M
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S1. PubMed ID: 19765251
    [No Abstract]   [Full Text] [Related]  

  • 36. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Summary--calcium receptors: potential targets for novel treatments for skeletal disease.
    Nemeth EF
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):416-7. PubMed ID: 15758288
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term results of surgery for lithium-associated hyperparathyroidism (Br J Surg 2010; 97:1680-1685).
    Varhaug JE
    Br J Surg; 2010 Nov; 97(11):1685-6. PubMed ID: 20890918
    [No Abstract]   [Full Text] [Related]  

  • 39. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the safety and rationale for cinacalcet posttransplant hyperparathyroidism and hypercalcemia.
    Coyne DW; Delos Santos R
    Am J Transplant; 2014 Nov; 14(11):2446-7. PubMed ID: 25223316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.